DESTiNED to help.
Developing a groundbreaking new technology capable of reversing tissue and organ calcification, saving billion of lives in the process.
We can help millions of people – every year.
Elastin is one of the major components of the extracellular matrix and provides elasticity and flexibility to all organs as the lung, heart, vessels, and skin. Elastic fibers expand and contract in the wall of blood vessels to circulate blood and oxygen trough the body.
Healthy elastin In a 6-year old child
Damaged Elastin in a 90 year old person
Although Elastin is one of the most stable proteins known, with a half-life approximately 74 years, Elastin production ceases and is no longer available in adulthood. Loss of elastic fibers due to age-related degradation, disease, or injury can lead to loss of tissue integrity and functionality.
Damaged elastin fibers weakens skin and arterial walls and shows up physically not only as sagging skin, but it also leads to aneurysms and strokes, neurological acuity, mobility, circulation, and impaired breathing.
Elastrin Therapeutics Inc.'s patented nanoparticle therapy is rejuvenating blood vessels through the targeted delivery of active agents. The therapy uses nanoparticles that are conjugated with antibodies that specifically bind to damaged elastin in the tissue. This targeted delivery allows the nanoparticles to effectively deliver active agents such as EDTA, which helps to de-calcify the tissue, and PGG, which promotes the formation of new, healthy elastin.
Once the nanoparticles have delivered their active agents to the targeted tissue, they work to stop the inflammation cascade and re-establish elasticity and compliance in the blood vessels and other tissues.
Elastin degradation is a leading contributor to heart and lung disease. Our team built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries.
The platform significantly improves the efficacy of drugs and eliminates side-effects by combining particle design with elastin targeting.
Orphan indications with severe arterial calcification
Generalized arterial calcification of infancy (GACI) and Pseudoxanthoma elasticum (PXE)
No therapies approved yet and those in development only halt progression of disease
Broad indications such as peripheral artery disease (PAD)
Plaque and calcification at the center of problem
27 million patients in North America and Europe
Universal platform that targets damaged elastic fiber in connective tissue
Improve safety and efficacy of drugs
By increasing drug concentrations at disease site
Launch broad therapy
Bring affordable preventive therapy